Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $42

Benzinga · 5d ago
Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from $40 to $42.